Loading
Life sciences · Journal article
Molecular Medicine Reports · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic syndrome (MetS) is a complex of disorders, characterized by insulin resistance accompanied by abdominal obesity, dyslipidemia, hypertension and impaired glucose metabolism.This group of conditions notably increases the risk of type 2 diabetes mellitus and cardiovascular or cerebrovascular diseases and has become a major global public health challenge.current treatments for MetS often fail to meet clinical needs owing to the limitations associated with single-target therapies and notable side effects.artemisinin-based drugs are primarily used as antimalarial drugs but have garnered widespread attention for their broad biological activities.Preclinical evidence suggests that artemisinin and its derivatives improve insulin sensitivity, regulate lipid metabolism, alleviate chronic inflammation and reshape the gut microbiota by modulating multiple metabolism-related signaling pathways, including aMP-activated protein kinase, Pi3K/akt, nF-κB and Toll-like receptor 4, indicating a potential therapeutic avenue for MetS.However, most of these findings are derived from cell-based and animal studies, while direct clinical evidence in patients with MetS remains limited. in the present review, the therapeutic potential and core molecular mechanisms of artemisinin and its derivatives for MetS are summarized and the challenges and opportunities for their future clinical translation are discussed.Contents 1. introduction 2. Structural basis and pharmacological effects of artemisinin and its derivatives 3. Mechanisms of artemisinin and its derivatives in regulating MetS 4. clinical applications and emerging therapeutic strategies for artemisinin and its derivatives 5. conclusion and outlook